The decline of IL6 might also contribute to the increase of IFNγ, as it is reported that IL6 could inhibit IFNγ expression in breast cancer.[15] All of the data suggested that Gp‐EVtPD1 treatment would elicit anti‐tumor immunity by blocking PD1/PDL1 axis. This evidence concerns the gene IL6 and breast carcinoma.